Bristol Pravachol/Aspirin Co-Package Not Precedent For Combo Submissions
Executive Summary
Bristol-Myers Squibb's Pravachol/aspirin combination should not be viewed as a precedent for approval of other combination products, FDA's Cardiovascular & Renal Drugs Advisory Committee members suggested July 18
You may also be interested in...
Bristol Pravigard PAC Set For August Launch At Pravachol AWP
Bristol-Myers Squibb will launch its pravastatin/aspirin combination Pravigard PAC in August at the same average wholesale price as the cholesterol-lowering agent Pravachol (pravastatin)
Bristol Pravigard PAC Set For August Launch At Pravachol AWP
Bristol-Myers Squibb will launch its pravastatin/aspirin combination Pravigard PAC in August at the same average wholesale price as the cholesterol-lowering agent Pravachol (pravastatin)
Bristol Pravachol/Aspirin Patient Compliance Study Suggested By Cmte.
Bristol-Myers Squibb should submit patient compliance data for its Pravachol/aspirin fixed-dose combination, FDA Cardiovascular-Renal Drugs Advisory Committee members suggested during a Jan. 18 meeting